End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.019 AUD | 0.00% | -5.00% | -5.00% |
30/04 | Transcript : Syntara Limited, Q3 2024 Earnings Call, Apr 30, 2024 | |
10/04 | Syntara Reaches 50% Recruitment in Phase 2 Trial for Bone Marrow Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-5.00% | 1.5Cr | |
+38.51% | 73TCr | |
+33.05% | 60TCr | |
-6.23% | 35TCr | |
+18.78% | 33TCr | |
+1.35% | 28TCr | |
+16.00% | 24TCr | |
+8.09% | 20TCr | |
-5.77% | 20TCr | |
+6.19% | 16TCr |
- Stock Market
- Equities
- SNT Stock
- News Syntara Limited
- Pharmaxis : Reports Good Tolerability in Increased Dose of Bone Marrow Cancer Treatment in Second Cohort Clinical Trial